Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 9 ... anti-CD20 ofatumumab and the anti-CD23 lumiliximab, thalidomide and its analog lenalidomide, the semi-synthetic flavonoid flavopiridol and other agents which are currently ...
2009 OCT 5 ... "To investigate the effect of thalidomide, CC-4047 (pomalidomide), CC-5013 (lenalidomide), and CC-10004 (apremilast) on gut LPMC TNF alpha and MMP-3 production in patients with ...
2009 OCT 12 ... should be taken in future trials to document arterial events with both thalidomide and lenalidomide." Martin and colleagues published their study in Clinical Lymphoma & ...
2009 NOV 1 ... in relapsed multiple myeloma. A Phase 3 trial evaluating carfilzomib in combination with lenalidomide and dexamethasone as a potential treatment option for patients with multiple myeloma is ...
2009 NOV 2 ... According to a study from the United States, "Lenalidomide and pomalidomide have both been evaluated clinically for their properties as anticancer ...
2009 OCT 12 ... According to recent research from the United States, "Lenalidomide is the first karyotype-selective therapeutic approved for the treatment of ...
2009 NOV 9 ... According to recent research from the United States, "Lenalidomide is an immunomodulatory drug (IMiD ™) with erythropoietic activity in ...
2009 SEP 14 ... temsirolimus, immunomodulatory and antiangiogenic agents including thalidomide and lenalidomide, and cyclin-dependent kinase inhibitors, as well as a renewed interest in older ...
2009 SEP 7 ... and in vitro using immunomodulatory drugs (IMiDs),' is now available. "Thalidomide and lenalidomide are FDA approved for the treatment of multiple myeloma and, along with pomalidomide, are ...
2009 SEP 28 ... (range, 3-13), including autologous transplantation in 20, thalidomide in all 23, lenalidomide in 17, and bortezomib in 19, 9 of whom were bortezomib-refractory. Two patients ...
2009 NOV 9 ... States conducted a study "To investigate the safety and efficacy of the combination of lenalidomide and prednisone in patients with myelofibrosis (MF). Forty patients with MF were ...
2009 NOV 2 ... diffuse large B-cell lymphoma and dacetuzumab in combination with Revlimid® (lenalidomide) for relapsed and refractory multiple myeloma; in addition, preclinical data will be ...
2009 OCT 12 ... treatment of multiple myeloma with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, leading to improved outcomes. High-dose therapy and autologous stem ...
2009 NOV 1 ... trial was undertaken to evaluate the toxicity of a novel regimen combining docetaxel and lenalidomide." "Patients with advanced solid tumors were eligible. Docetaxel was ...
